Illustration of a deceptive colon tumor with hidden cancer.

Hidden Danger: When a Seemingly Harmless Colon Tumor Turns Aggressive

Jordan Keane monogram
Jordan Keane in Health & Wellness October 2026 • 4 min read.

"Learn how a routine colonoscopy revealed an unusual case of adenocarcinoma hiding beneath the surface, challenging common perceptions of submucosal tumors."


Colonoscopies are a vital tool in detecting and preventing colorectal cancer, the third most common cancer diagnosed in the United States. These routine screenings allow doctors to identify and remove potentially cancerous growths, often before they pose a serious threat. But what happens when a seemingly harmless tumor turns out to be something far more sinister?

A recent case study published in a leading medical journal highlights the complexities of diagnosing colorectal cancers. It tells the story of a 64-year-old woman who underwent a colonoscopy for abdominal discomfort. During the procedure, doctors discovered a small, protruded lesion in her descending colon, initially believed to be a submucosal tumor (SMT) – a type of growth that typically develops beneath the inner lining of the colon.

However, further investigation revealed a surprising and concerning truth: the presumed SMT was actually an adenocarcinoma, an aggressive form of cancer that had been lurking beneath the surface. This unusual case challenges conventional understanding and underscores the importance of vigilant screening and advanced diagnostic techniques.

AI Search Multiple angles on this topic

Colorectal Cancer by the Numbers

Colorectal cancer ranks as the fourth most common cancer in both men and women in the United States and is the fourth leading cause of cancer-related deaths. In 2023, approximately 155,662 new colorectal cancers were reported, and 54,468 people died from the disease in 2024. The American Cancer Society projects about 108,860 new colon cancer cases and 49,990 new rectal cancer cases for 2026. Diagnosis rates have dropped overall since earlier decades, though the burden remains substantial.

Conventional Treatments and Their Drawbacks

Standard therapeutic approaches to colorectal cancer—including surgery, chemotherapy, and radiotherapy—have contributed to reduced incidence and death rates, with five-year survival rates improving over time. However, conventional therapies are non-specific and carry numerous secondary complications, highlighting the need for more targeted interventions. A multidisciplinary approach is considered essential, with en bloc resection recommended for resectable colon cancer. Personalized medicine offers advantages but also faces significant challenges, particularly in middle- and low-income countries.

Key Milestones in Colon Cancer Understanding

The understanding of colorectal cancer has evolved significantly over past decades, building on foundational discoveries in genetics, pathology, and tumor biology. Early identification of adenocarcinoma as the predominant histological subtype helped shape diagnostic and treatment frameworks. Advances in molecular characterization have since revealed the heterogeneity within colorectal tumors, refining how clinicians classify and manage the disease.

The Silent Threat: Unmasking Adenocarcinoma in Disguise

Illustration of a deceptive colon tumor with hidden cancer.

Submucosal tumors (SMTs) are often benign, slow-growing masses that develop in the submucosa, a layer of tissue beneath the inner lining of the colon. While some SMTs can be cancerous, many are non-cancerous growths like lipomas (fatty tumors) or leiomyomas (smooth muscle tumors). Their seemingly harmless nature often leads to a less aggressive approach in diagnosis and treatment.

In the case study, the tumor's appearance mimicked that of a typical SMT. It was entirely covered by normal-appearing mucosa, the inner lining of the colon. This made it difficult to suspect malignancy based on initial visual examination alone. Adding to the complexity, a small adenomatous polyp, another type of growth, was found nearby.

  • Endoscopic Submucosal Dissection (ESD): A precise technique used to remove suspicious lesions from the digestive tract.
  • Histological Examination: Microscopic analysis of tissue samples to identify cancerous cells and determine the tumor's characteristics.
  • Adenocarcinoma: An aggressive type of cancer that originates in glandular cells.
AI Search Multiple angles on this topic

Recent Advances in Colorectal Cancer Research

Colorectal cancer remains a formidable global health challenge characterized by uncontrolled cell proliferation and significant socioeconomic burden, with projections anticipating a substantial increase in new cases. Recent research highlights emerging therapeutic approaches with potential to soon translate into standard care. Studies published in 2026 continue to explore the role of various biological mechanisms in colorectal cancer development and provide overviews of their therapeutic potential. The field is actively working toward innovative strategies to address the growing strain on healthcare systems worldwide.

Challenges and Limitations in Current Practice

Conventional approaches such as surgery, chemotherapy, and radiotherapy exhibit inherent limitations that necessitate exploration of innovative diagnostic and therapeutic strategies. Colorectal cancer staging remains challenging, with ongoing efforts to improve accuracy and consistency in how tumors are classified. Recent molecular characterization has revolutionized understanding of tumor heterogeneity, particularly regarding tumor sidedness, yet translating these insights into clinical practice presents ongoing difficulties. The most common form, adenocarcinoma, develops from gland-forming cells that accumulate genetic changes and grow uncontrollably, underscoring the complexity of the disease.

Mucinous vs. Non-Mucinous Adenocarcinoma

Mucinous adenocarcinoma is a histological subtype of colorectal cancer whose oncologic behavior differs from nonmucinous adenocarcinoma. Studies indicate that mucinous adenocarcinoma is characterized by more aggressive behavior compared to its non-mucinous counterpart. Research comparing clinical outcomes and postoperative recovery between the two subtypes aims to better understand their distinct trajectories. Colorectal cancer encompasses multiple tumor types, ranging from the most common adenocarcinoma to rarer forms such as signet-ring cell carcinoma.

To thoroughly assess both the SMT and the coexisting polyp, doctors performed an endoscopic submucosal dissection (ESD), a procedure that allows for the removal of lesions for further examination. The subsequent pathological analysis revealed the unsettling truth: the SMT was, in fact, a moderately differentiated tubular adenocarcinoma, confined to the submucosal layer. This unexpected finding highlighted the importance of advanced diagnostic techniques and vigilance in identifying potentially aggressive tumors, even when initial signs appear benign.

The Takeaway: Vigilance and Advanced Diagnostics are Key

This unusual case underscores the critical importance of regular colonoscopies and the use of advanced diagnostic techniques. While submucosal tumors may often appear benign, this case demonstrates that a seemingly harmless appearance can be deceiving. Vigilance, coupled with thorough examination and pathological analysis, is crucial for early and accurate diagnosis, ultimately improving patient outcomes in the fight against colorectal cancer.

AI Search Multiple angles on this topic

Expert Perspectives on Colorectal Cancer Care

Colorectal cancer management continues to be shaped by the interplay between established treatment paradigms and emerging evidence. Clinicians increasingly emphasize the importance of tailoring strategies to individual patient profiles, balancing efficacy with quality of life considerations. The growing body of research underscores both the progress made and the gaps that remain in optimizing outcomes for all patients.

Emerging Trends and Therapeutic Frontiers

The evolving landscape of colorectal cancer includes shifting incidence trends and epidemiological characteristics at global, regional, and national levels. Recent statistics from 2026 provide updated projections that can inform healthcare policy formulation. Immunotherapy has become a significant component of management, with pembrolizumab approved in 2017 for select molecular subtypes. Targeted therapy breakthroughs and advances in circulating tumor DNA detection represent promising developments highlighted at recent oncology conferences.

Systemic Treatment Landscape in 2025

The annual review of systemic medical treatment for colorectal cancer in 2025 provides a comprehensive overview of the therapeutic landscape, including chemotherapy regimens, targeted agents, and immunotherapies. This review synthesizes evidence on treatment efficacy and safety profiles to guide clinical decision-making. The evolving treatment paradigms reflect both advances in understanding tumor biology and the ongoing need to address resistance mechanisms and access disparities.

Patient Experiences and Quality of Life

Beyond clinical data, colorectal cancer profoundly affects patients' daily lives, emotional well-being, and relationships. The burden of treatment extends to caregivers and families who navigate the complexities of diagnosis, therapy, and recovery. Addressing the human dimension of cancer care remains essential for improving overall outcomes and patient satisfaction.

How often deep invasion predicted lymph-node spread

  • 2.6% absolute riskAcross eight studies of 1,146 patients, the absolute risk of lymph-node metastasis when deep submucosal invasion was considered alone was 2.6%; the pooled incidence rate was 2.83 (95% CI, 1.66–4.78).[1]

What the risk comparisons suggest

Deep invasion by itself did not distinguish cases with lymph-node metastasis as clearly as some other tumor features did. In the multivariable analysis, its association was not statistically significant, while poor differentiation, high-grade tumor budding, and lymphovascular invasion were significant predictors. This comparison suggests depth alone is an incomplete basis for estimating spread; it does not establish an individual tumor’s outcome.[1]

The low absolute risk reported when deep invasion was treated as a solitary factor underscores that a single feature does not capture the full range of risk. The evidence summarized here concerns associations across groups, not a prediction for any one person.[1]

How SMT-like cancers compare with broader risk evidence

In a comparison of small colorectal cancers, the SMT-like group had a smaller median diameter than the control group; the reported control value is incomplete, so the size difference cannot be quantified from this figure.[2]

A report on dome-type carcinoma suggests that the subtype may progress to usual-type adenocarcinoma; some previously reported cases contained both components. That possibility is a proposed explanation for rarity, not proof of a progression pathway.[3]

What remains unresolved about hidden tumor types

  • Could additional cases and phenotypic characterization establish dome-type carcinoma as a distinct colorectal adenocarcinoma subtype, and clarify whether its proposed relationship to M-cells matters?[3]
  • How can submucosal micropapillary adenocarcinoma be identified before resection when superficial biopsies may sample only benign ulcerated mucosa?[4]
  • What accounts for disagreement between forceps-biopsy histology and the resected specimen, and how might that affect interpretation of a suspected submucosal lesion?[5]

Terms for interpreting the evidence

M-cells
Cells proposed as a possible origin for dome-type carcinoma, based on its phenotypic features and association with gut-associated lymphoid tissue.[3]

Sources

  1. Deep Submucosal Invasion Is Not an Independent Risk Factor for Lymph Node Metastasis in T1 Colorectal Cancer: A Meta-Analysis. (pubmed.ncbi.nlm.nih.gov)
  2. Small colorectal cancers resembling submucosal tumor with massive submucosal invasion and lymph node metastasis: A report of two cases and review of the literature. (pubmed.ncbi.nlm.nih.gov)
  3. Dome-type carcinoma of the colon; a rare variant of adenocarcinoma resembling a submucosal tumor: a case report (pmc.ncbi.nlm.nih.gov)
  4. Submucosal micropapillary adenocarcinoma of the sigmoid colon: A distinct and aggressive subtype of adenocarcinoma (pmc.ncbi.nlm.nih.gov)
  5. Diagnostic Accuracy and Interobserver Agreement in Predicting the Submucosal Invasion of Colorectal Tumors Using Gross Findings, Pit Patterns, and Microvasculatures (pmc.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What is a submucosal tumor (SMT), and why are they typically considered 'harmless'?

Submucosal tumors (SMTs) are growths that develop in the submucosa, which is a layer of tissue beneath the inner lining of the colon. They are often considered harmless because many are benign, slow-growing masses such as lipomas (fatty tumors) or leiomyomas (smooth muscle tumors). However, as demonstrated in a specific case, some SMTs can mask more aggressive conditions like adenocarcinoma. The 'harmless' perception can lead to a less aggressive initial diagnostic approach, which is why thorough examination is crucial.

2

How can a seemingly benign submucosal tumor (SMT) actually be an aggressive adenocarcinoma?

A submucosal tumor (SMT) can mask an aggressive adenocarcinoma when the cancerous growth is hidden beneath the normal-appearing mucosa, the inner lining of the colon. In these cases, the tumor's external appearance mimics that of a typical, benign SMT, making it difficult to suspect malignancy based on initial visual examination alone. This is why techniques like endoscopic submucosal dissection (ESD) and histological examination are essential to uncover the true nature of the tumor.

3

What role did the endoscopic submucosal dissection (ESD) play in diagnosing the adenocarcinoma in the case?

Endoscopic submucosal dissection (ESD) was crucial in diagnosing the adenocarcinoma because it allowed doctors to remove the suspicious lesion, initially believed to be a benign submucosal tumor (SMT), from the digestive tract. This technique enabled a thorough pathological analysis of the tissue sample. Without the ESD, the adenocarcinoma, which was lurking beneath the surface, might have gone undetected for a longer period, potentially leading to a delayed diagnosis and treatment.

4

Why is histological examination so important in cases involving submucosal tumors (SMTs)?

Histological examination is essential in cases involving submucosal tumors (SMTs) because it involves the microscopic analysis of tissue samples to identify cancerous cells and determine the tumor's characteristics. In cases where a tumor appears benign on the surface, such as the adenocarcinoma mimicking an SMT, histological examination can reveal the true, aggressive nature of the growth. This level of analysis is critical for accurate diagnosis and appropriate treatment planning.

5

What are the broader implications of this case regarding colonoscopies and the detection of colorectal cancer?

This case underscores the critical importance of regular colonoscopies and the use of advanced diagnostic techniques. Even when a submucosal tumor (SMT) appears benign during a colonoscopy, there is a possibility that it could be masking an aggressive cancer like adenocarcinoma. Therefore, vigilance, thorough examination, and pathological analysis, including techniques like endoscopic submucosal dissection (ESD) and histological examination, are crucial for early and accurate diagnosis. This ultimately improves patient outcomes in the fight against colorectal cancer by ensuring that potentially dangerous growths are identified and treated promptly.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.